Metformin does not affect cancer risk: A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial

Diabetes Care

Volumn 37, Issue 9, 2014, Pages 2522-2532

  Tsilidis, Konstantinos K ^a,b   Capothanassi, Despoina ^a   Allen, Naomi E ^c   Rizos, Evangelos C ^d   Lopez, David S ^e   Van Veldhoven, Karin ^f,h   Sacerdote, Carlotta ^g   Ashby, Deborah ⁱ   Vineis, Paolo ^f,g   Tzoulaki, Ioanna ^a,f   Ioannidis, John P A ^j  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g Human Genetics Foundation   (Italy)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIBORNURIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLYMIDINE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; VILDAGLIPTIN; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL PRACTICE; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE DURATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; GLYCEMIC CONTROL; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKEMIA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PANCREAS CANCER; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RETROSPECTIVE STUDY; SMOKING; STOMACH CANCER; TREATMENT DURATION; UNITED KINGDOM; VERY ELDERLY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; FOLLOW UP; HEALTH CARE PLANNING; INCIDENCE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEALTH RESOURCES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INTENTION TO TREAT ANALYSIS; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84906691535     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0584     Document Type: Article

References (30)

1. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013;37:207-218.
2. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013;62:922-934.
3. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-2603.
4. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-2673.
5. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008;19:766-779.
6. Walley T,Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-1099.
7. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425.
8. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-689.
9. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
10. Cooper R, Mishra G, Clennell S, Guralnik J, Kuh D. Menopausal status and physical performance in midlife: findings from a British birth cohort study. Menopause 2008;15:1079-1085.
11. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-1646.
12. BuzzaiM, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-6752.
13. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273.
14. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-1308.
15. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabeteswho use sulfonylureas or insulin. Diabetes Care 2006;29:254-258.
16. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777.
17. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-1305.
18. Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care 2005;28:590-594.
19. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ.Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-326.
20. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137:482-488.
21. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625.
22. Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011;34:923-929.
23. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:349-357.
24. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-665.
25. Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2013;22:1877-1883.
26. Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129.
27. Redaniel MT, Jeffreys M, May MT, Ben- Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control 2012;23:1785-1795.
28. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20: 337-344.
29. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
30. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.